<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Immunology</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Immunology</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский иммунологический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1028-7221</issn><issn publication-format="electronic">2782-7291</issn><publisher><publisher-name xml:lang="en">Russian Society of Immunology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">16</article-id><article-id pub-id-type="doi">10.31857/S102872210005025-2</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">CHARACTERISTICS OF IMMUNE RESPONSE INDUCED BY GMDP PEPTIDE MIMETIC RN: A COMPARATIVE ANALYSIS WITH MURAMYLPEPTIDES</article-title><trans-title-group xml:lang="ru"><trans-title>ОСОБЕННОСТИ ИММУННОГО ОТВЕТА, ИНДУЦИРОВАННОГО «GMDP-ОБРАЗНЕСУЩИМ» ПЕПТИДОМ RN: СРАВНИТЕЛЬНЫЙ АНАЛИЗ С МУРАМИЛПЕПТИДАМИ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Alekseeva</surname><given-names>L. G.</given-names></name><name xml:lang="ru"><surname>Алексеева</surname><given-names>Л. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Ph.D, senior researcher, Laboratory of Peptide Chemistry,</p><p>117997, Moscow, Miklukho-Maklaya ul., 16/10</p></bio><bio xml:lang="ru"><p>к. х. н., старший научный сотрудник лаборатории химии пептидов,</p><p>117997, г. Москва, ул. Миклухо-Маклая, 16/10</p></bio><email>luda.alekseeva@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Meshcheryakova</surname><given-names>E. A.</given-names></name><name xml:lang="ru"><surname>Мещерякова</surname><given-names>Е. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Ph.D., researcher, Laboratory of Peptide Chemistry,</p><p>Moscow</p></bio><bio xml:lang="ru"><p>к. х. н., научный сотрудник лаборатории химии пептидов,</p><p>Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Laman</surname><given-names>A. G.</given-names></name><name xml:lang="ru"><surname>Ламан</surname><given-names>А. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>senior researcher, Laboratory of Immunochemistry,</p><p>Pushchino, Moscow region</p></bio><bio xml:lang="ru"><p>к. б. н., старший научный сотрудник лаборатории иммунохимии,</p><p>Пущино, Московская область</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Andronova</surname><given-names>T. M.</given-names></name><name xml:lang="ru"><surname>Андронова</surname><given-names>Т. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Ph.D., president,</p><p>Moscow</p></bio><bio xml:lang="ru"><p>к. х. н., президент компании,</p><p>Москва</p></bio><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ivanov</surname><given-names>V. T.</given-names></name><name xml:lang="ru"><surname>Иванов</surname><given-names>В. Т.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>academician, Leader of Laboratory of Peptide Chemistry,</p><p>Moscow</p></bio><bio xml:lang="ru"><p>д. х. н., академик, заведующий лабораторией химии пептидов,</p><p>Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">M.M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic Chemistry, RAS</institution></aff><aff><institution xml:lang="ru">ФГБУН Института биоорганической химии им. академиков М. М. Шемякина и Ю. А. Овчинникова РАН</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Branch of M. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic Chemistry, RAS</institution></aff><aff><institution xml:lang="ru">ФГБУН Филиал Института биоорганической химии им. академиков М. М. Шемякина и Ю. А. Овчинникова РАН</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Joint-Stock Company “PEPTEK”</institution></aff><aff><institution xml:lang="ru">АО «ПЕПТЕК»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2019-01-15" publication-format="electronic"><day>15</day><month>01</month><year>2019</year></pub-date><volume>22</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>86</fpage><lpage>92</lpage><history><date date-type="received" iso-8601-date="2020-04-02"><day>02</day><month>04</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-04-02"><day>02</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2019, Alekseeva L.G., Meshcheryakova E.A., Laman A.G., Andronova T.M., Ivanov V.T.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2019, Алексеева Л.Г., Мещерякова Е.А., Ламан А.Г., Андронова Т.М., Иванов В.Т.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="en">Alekseeva L.G., Meshcheryakova E.A., Laman A.G., Andronova T.M., Ivanov V.T.</copyright-holder><copyright-holder xml:lang="ru">Алексеева Л.Г., Мещерякова Е.А., Ламан А.Г., Андронова Т.М., Иванов В.Т.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://rusimmun.ru/jour/article/view/16">https://rusimmun.ru/jour/article/view/16</self-uri><abstract xml:lang="en"><p>To study the mechanism of action of the GMDP peptide mimetic RN, its eff ect on the expression level of mRNA of the pro-infl ammatory cytokines IL-1β and TNF-α and some molecules involved in the activation of the NF-kB signaling pathway in human leukemic monocyte cells THP-1 was evaluated. For comparison, GMDP itself and its two analogues with well-characterized biological activity, GMDPacid and GMDP-Lys, were used. All compounds demonstrated signifi cant diff erences during the development of the immune response: GMDP-Lys turned out to be the strongest stimulator of the immune response; GMDP-acid to a greater extent enhanced the expression of the p100/p52 subunit (NF-kB2) and to a lesser extent the expression of IL-1β in comparison with GMDP; the peculiarities of peptide RN response were low level of IL-1β production and stimulation of the adapter protein RIP2 of innate immunity NOD2 receptor. All compounds studied are valuable tools for fi nding new ways for immune response correction.</p></abstract><trans-abstract xml:lang="ru"><p>Для изучения механизма действия пептидного миметика мурамилпептида GMDP RN оценивалось его влияние на уровень экспрессии мРНК провоспалительных цитокинов IL-1β и TNF-α и молекул, принимающих участие в активации NF-kB сигнального пути, в клетках линии лейкемических моноцитов человека ТНР-1. Для сравнения были использованы собственно GMDP и два его аналога с хорошо охарактеризованной биологической активностью – GMDP-кислота и GMDP-Lys. Все соединения демонстрировали значительные отличия в ходе развития иммунного ответа: наиболее сильным стимулятором иммунного ответа оказался GMDP-Lys; GMDPкислота в большей степени усиливала экспрессию субъединицы р100/р52 (NF-kB2) и в меньшей степени экспрессию IL-1β по сравнению с GMDP; особенностями пептида RN являлись низкий уровень продукции IL-1β и стимуляция адапторного белка RIP2 для рецептора NOD2 врождённого иммунитета. Все исследованные соединения являются ценными инструментами для поиска новых способов коррекции иммунного ответа.</p></trans-abstract><kwd-group xml:lang="en"><kwd>muramylpeptides</kwd><kwd>NOD2 and TLR4 receptors</kwd><kwd>NF-kB</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>мурамилпептиды</kwd><kwd>рецепторы NOD2 и TLR4</kwd><kwd>NF-kB</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена при финансовой поддержке РФФИ в рамках научных проектов 13-04- 02008а и 16-04-01152а и АО «Пептек».</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1. Grubbs H., Whitten R. A. Physiology, Active Immunity. StatPearls Publishing; Treasure Island (FL) 2018.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2. Belkaid Y., Harrison O. J. Homeostatic Immunity and the Microbiota. Immunity 2017, 46(4), 562–576.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3. Yang, Han. Z., Oppenheim J. J. Alarmins and immunity. Immunol Rev. 2017, 280(1), 41–56.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4. Tang J., Wu Z. Y., Dai R. J., Ma J., Gong G. Z. Hepatitis B virus-persistent infection and innate immunity defect: Cell-related or virus-related? World J. Clin. Cases 2018, 6(9), 233–241.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5. Man S. M. Infl ammasomes in the gastrointestinal tract: infection, cancer and gut microbiota homeostasis. Nat Rev Gastroenterol. Hepatol. 2018, 15(12), 721–737.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6. McGonagle D., Watad A., Savic S. Novel immunological based classification of rheumatoid arthritis with therapeutic implications. Autoimmun. Rev. 2018, 17(11), 1115–1123.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>7. Ozinsky A., Smith K. D., Hume D., Underhill D. M. Cooperative induction of pro-infl ammatory signaling by Toll-like receptors. J Endotoxin Res. 2000, 6(5), 393–396.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>8. Patin E. C., Orr S. J., Schaible U. E. Macrophage inducible C-Type Lectin as a multifunctional player in immunity. Front. Immunol. 2017, 8, 861.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>9. Elinav E., Strowig T., Henao-Mejia J., Flavell R. A. Regulation of the antimicrobial response by NLR proteins. Immunity 2011, 34, 665–679.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10. Liu Y., Olagnier D., Lin R. Host and Viral Modulation of RIG-I–Mediated Antiviral Immunity. Front. Immunol. 2017, 7, 662.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>11. Poltorak A., He X., Smirnova I., Liu M. Y., Van H. C., Du X., Birdwell D., Alejos E., Silva M., Galanos C., Freudenberg M., Ricciardi-Castagnoli P., Layton B., Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282, 2085–2088.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>12. Dziarski R. Recognition of bacterial peptidoglycan by the innate immune system. Cell Mol. Life Sci. 2003, 60(9), 1793–804.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>13. Panaro M. A., Acquafredda A., Sisto M., Lisi. S, Maffione A. B., Mitolo V. Biological role of the N-formyl peptide receptors. Immunopharmacol. Immunotoxicol. 2006, 28, 103–127.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>14. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato. S, Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408, 740–745.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>15. Girardin S. E., Boneca I. G., Garneiro L. A., Antignac A., Jehanno M., Viala J., Tedin K., Labigne A., Zahringer U., Coyle A. J., DiStefano P. S., Bertin J., Sansonetti P. J., Philpott D. J. Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science 2003, 300, 1584–1587.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>16. Girardin S. E., Boneca I. G., Viala J., Chamaillard M., Labigne A., Thomas G., Philpott D. J., Sansonetti P. J. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 2003, 278, 8869–8872.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>17. Barnich N., Aguirre J. E., Reinecker H. C., Xavier R., Podolsky D. K. Membrane recruitment of NOD2 in intestinal epithelial cells is essential for nuclear factor- {kappa}B activation in muramyl dipeptide recognition. J. Cell Biol. 2005, 170, 21–26.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>18. Chen G., Shaw M. H., Kim Y. G., Nuñez G. NOD-like receptors: role in innate immunity and inflammatory disease. Annu. Rev. Pathol. 2009, 4, 365–98.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>19. Ростовцева Л. И., Андронова Т. М., Малькова В. П., Сорокина И. Б., Иванов В. Т. Синтез и противовопухолевое действие гликопептидов, содержащих N-ацетилглюкозаминил-(β1→4)-N-аце тил му рамил-дисахаридное звено. Биоорган. химия 1981, 7(12), 1843–1858.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>20. Ламан А. Г., Шепеляковская А. О., Бозиев Х. М., Савинов Г. В., Бровко Ф. А., Несмеянов В. А. Метод получения адъювантно активных пептидов – миметиков GMDP с использованием моноклональных антител и комбинаторных библиотек пептидов в формате фагового дисплея. Биоорган. химия 2010, 36(2), 170–177.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>21. Livak K. J., Schmittgen T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(–Delta Delta C(T)) Method. Methods 2001, 25(4), 402–408.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>22. Pfaffl M. W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29(9), e45.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>23. Laman A. G., Shepelyakovskaya A. O., Boziev Kh. M., Savinov G. V., Baidakova L. K., Chulin A. N., Chulina I. A., Korpela T., Nesmeyanov V. A., Brovko F. A. Structural modification eff ects on bioactivities of the novel 15-mer peptide adjuvant. Vaccine 2011, 29(44), 7779–7784.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>24. Мещерякова Е. А., Гурьянова С. В., Макаров Е. А., Андронова Т. М., Иванов В. Т. Структурно-функци о наль ное исследование глюкозаминилмурамоилпептидов. Влияние химической модификации N-ацетилглюкозаминил-N-ацетил му ра мо ил пепти да на его иммуномодулирующие свойства in vivo и in vitro. Биоорган. химия 1991, 17(9), 1157–1165.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>25. Fritz J. H., Girardin S. E., Fitting C., Werts C., MenginLecreulx D., Caroff M., Cavaillon J. M., Philpott D. J., Adib-Conquy M. Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists. Eur. J. Immunol. 2005, 35(8), 2459–2470.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>26. Мещерякова Е. А., Алексеева Л. Г., Андронова Т. М. Роль мурамилпептидов в клеточной модели воспалительного иммунного ответа, Российский иммунологический журнал, 2015, 9(18), 3, 301–323.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>27. Concetti J., Wilson C. L. NFKB1 and Cancer: Friend or Foe? Cells 2018, 7(9), pii: E133.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>28. Martinon F., Agostini L., Meylan E., Tschopp J. Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr. Biol. 2004, 14(21), 1929–1934.</mixed-citation></ref></ref-list></back></article>
